Lamellar Ichthyosis Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The lamellar ichthyosis market reached a value of USD 5.3 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 8.4 Million by 2035, exhibiting a growth rate (CAGR) of 4.17% during 2025-2035.

The lamellar ichthyosis market has been comprehensively analyzed in IMARC's new report titled "Lamellar Ichthyosis Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Lamellar ichthyosis is a rare and inherited skin disorder that falls under the broader category of ichthyosis, which refers to a group of genetic conditions characterized by dry, scaly skin. This particular type is caused by mutations in the gene responsible for forming a protein called transglutaminase-1, leading to the abnormal development of the skin's protective barrier. The symptoms of the ailment typically manifest at birth or within the first few weeks of life. Individuals suffering from the illness may present with thick, plate-like scales covering large areas of their body, often resembling fish scales. The skin can be dry, rough, and prone to cracking, which can cause discomfort and susceptibility to infections. Moreover, these scales may affect the patient's range of motion and lead to restricted movement. The diagnosis of lamellar ichthyosis involves a thorough examination of the skin and family history analysis. Skin biopsies and genetic testing are also crucial steps in confirming the condition.

To get more information of this market, Request Sample

The rising prevalence of somatic mutations in the TGM1 gene, which result in the impaired production of the enzyme transglutaminase-1, leading to the buildup of scale-like skin, particularly affecting the face and body regions, is primarily driving the lamellar ichthyosis market. In addition to this, the escalating adoption of numerous effective medications, including emollients, keratolytics, retinoids, etc., to alleviate symptoms of the ailment and enhance skin barrier function is fostering a positive outlook for the market. Moreover, the widespread implementation of physical and occupational therapies to increase treatment response is further bolstering the market growth. These therapies play a crucial role in managing the condition by promoting mobility, improving limb function, and enhancing overall motor skills. Apart from this, the increasing utilization of phototherapy, since it involves exposing the affected skin to controlled levels of ultraviolet light, thereby boosting the quality of life for individuals suffering from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy that works by introducing functional genetic material to correct or replace the faulty TGM1 gene responsible for the disease, providing long-term relief to patients, is expected to drive the lamellar ichthyosis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the lamellar ichthyosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for lamellar ichthyosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lamellar ichthyosis market in any manner

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the lamellar ichthyosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the lamellar ichthyosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current lamellar ichthyosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the lamellar ichthyosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the lamellar ichthyosis across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the lamellar ichthyosis across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of incident cases (2019-2035) of lamellar ichthyosis across the seven major markets?
• What is the number of incident cases (2019-2035) of lamellar ichthyosis by age across the seven major markets?
• What is the number of incident cases (2019-2035) of lamellar ichthyosis by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with lamellar ichthyosis across the seven major markets?
• What is the size of the lamellar ichthyosis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend lamellar ichthyosis of?
• What will be the growth rate of patients across the seven major markets?

Lamellar Ichthyosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for lamellar ichthyosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the lamellar ichthyosis market?
• What are the key regulatory events related to the lamellar ichthyosis market?
• What is the structure of clinical trial landscape by status related to the lamellar ichthyosis market?
• What is the structure of clinical trial landscape by phase related to the lamellar ichthyosis market?
• What is the structure of clinical trial landscape by route of administration related to the lamellar ichthyosis market?